Pyrojas Inc.
Biotechnology company developing immune therapies that use patient-derived whole tumor cells and modular cell-engineering to generate durable anti-tumor T cell memory. Work emphasizes autologous whole-tumor-cell vaccine engineering, rapid non-viral cell engineering, tumor microenvironment modulation modules for adoptive cell therapies, preclinical translation, and licensing collaborations with academic and industry partners.
Industries
N/A
Nr. of Employees
small (1-50)
Pyrojas Inc.
Products
Patient-derived whole tumor cell vaccine (autologous whole-cell vaccine)
Autologous vaccine approach using a patient’s entire tumor as the immunogen to present the full antigenic landscape and induce diversified T cell responses.
Modular T cell function boosting module for adoptive cell therapies
A plug-in module engineered to be integrated into adoptive cell therapies that secretes peptides to neutralize suppressive signals in the tumor microenvironment and enhance persistence and cytotoxicity.
Patient-derived whole tumor cell vaccine (autologous whole-cell vaccine)
Autologous vaccine approach using a patient’s entire tumor as the immunogen to present the full antigenic landscape and induce diversified T cell responses.
Modular T cell function boosting module for adoptive cell therapies
A plug-in module engineered to be integrated into adoptive cell therapies that secretes peptides to neutralize suppressive signals in the tumor microenvironment and enhance persistence and cytotoxicity.
Services
Commercial licensing of integration-ready modules that enhance T cell function in suppressive tumor microenvironments for incorporation into adoptive cell therapy pipelines.
Commercial licensing of integration-ready modules that enhance T cell function in suppressive tumor microenvironments for incorporation into adoptive cell therapy pipelines.
Expertise Areas
- Autologous cancer vaccine development
- Tumor immunology and T cell memory
- Cell engineering (non-viral methods)
- Tumor microenvironment modulation
Key Technologies
- Autologous whole-tumor-cell vaccine
- Non-viral cell engineering
- Adjuvant-enhanced vaccine formulation
- Engineered secretion of immunomodulatory peptides
News & Updates
Reported 100% disease control in preclinical models, including prevention of tumor growth and clearance of established tumors (preclinical data).
Stated support and backing from National Cancer Institute and industry partners used to advance translational development.
Reported 100% disease control in preclinical models, including prevention of tumor growth and clearance of established tumors (preclinical data).
Stated support and backing from National Cancer Institute and industry partners used to advance translational development.